To search for subunit vaccine candidates, immunogenic chlamydial antigens identified in
humans were evaluated for protection against both infection and pathology in a mouse …

The accumulated body of evidence has provided important guiding principles for Chlamydia
vaccine development. They are:(i) whole‐organism vaccine preparations may be …

The failure of the inactivated Chlamydia-based vaccine trials in the 1960s has led
researchers studying Chlamydia to take cautious and rational approaches to develop safe …

Chlamydia trachomatis is a major cause of sexually transmitted disease (STD) for which a
vaccine is needed. CD4+ T-helper type 1 (Th1) cell-mediated immunity is an important …

The clinically relevant pathologic consequences of primary ocular, genital, or respiratory
human infection by members of the genus Chlamydia are conjunctivitis, cervicitis, urethritis …

Bacteria of the genus Chlamydia cause a plethora of ocular, genital and respiratory
diseases that continue to pose a considerable public health challenge worldwide. The major …

The ultimate goal of current chlamydial vaccine efforts is to utilise either conventional or
modern vaccinology approaches to produce a suitable immunisation regimen capable of …

Background The chlamydial proteins CT443 (OmcB) and CT521 (rl16) have previously been
identified as human B and/or T cell targets during a chlamydial infection in humans. Here we …

Vaccine development for Chlamydia species has progressed on several research fronts,
including knowledge of the components of the immune response required for immunity and …

Chlamydia trachomatis sexually transmitted infections cause considerable morbidity and
socioeconomic burden worldwide, despite significant advances in our understanding of the …